Highlights

  • Third quarter Revenue rose 4% to USD 94.9 million, with software revenue up 11% to USD 48.8 million.
  • Certara completed the sale of its Regulatory and Medical Writing Business to Veristat on May 8, 2026.
  • Cash and cash equivalents rose to USD 214.9 million from USD 189.4 million at the end of 2025.
  • Management narrowed its 2026 revenue growth outlook to 2% to 3% and set adjusted EPS at USD 0.31 to USD 0.34.

Certara, Inc. (NASDAQ:CERT) shares were trading near their 52-week high at USD 12.05 on November 6, 2026, down 1.07% on the day. The biosimulation software and services group completed the sale of its Regulatory and Medical Writing business in May, approved a new USD 50 million share repurchase program in August, and reported third quarter results on November 5 with a narrowed 2026 revenue growth range.

Based in Radnor, Pennsylvania, Certara is a Delaware corporation that delivers software and technology-driven services for biosimulation across drug discovery, preclinical and clinical research, regulatory submissions and market access. It reports a single segment and operates in the United States, Canada, Europe, Japan, China, India, Australia and other markets. Certara has a market Capitalization of USD 1.84 billion, and no price to Earnings ratio applies because it reported a net loss for the nine months. Its fiscal year ends December 31.

Third Quarter Results

Revenue from continuing operations was USD 94.9 million against USD 90.9 million a year earlier. Software revenue rose 11% to USD 48.8 million, while services revenue slipped 2% to USD 46.1 million. Management called it the first double-digit organic software growth quarter in two years. Total bookings were USD 92.5 million, up 4%.

Cost of revenues fell 6% to USD 31.4 million. General and administrative expense rose 11% to USD 27.0 million, and management tied USD 4.8 million of Operating Expense to reorganization, severance and executive recruiting costs. Income from operations was USD 2.3 million against a loss of USD 0.6 million. The loss from continuing operations narrowed to USD 3.6 million from USD 4.8 million, or USD 0.02 per share against USD 0.03.

Income from discontinued operations of USD 9.2 million lifted Net Income to USD 5.6 million, or USD 0.04 per diluted share, against USD 1.5 million, or USD 0.01. Adjusted EBITDA, a non-GAAP measure, rose 6% to USD 30.2 million, a 31.8% margin.

For the nine months, revenue was USD 282.3 million against USD 275.3 million, and loss from operations was USD 4.1 million against income from operations of USD 11.4 million. Net loss was USD 58.4 million, or USD 0.38 per share, against net income of USD 4.3 million, which includes a USD 37.0 million loss from discontinued operations.

Divestiture, Balance Sheet and Capital Returns

Certara agreed to sell its Regulatory and Medical Writing business on April 21 and closed the deal on May 8. It has received USD 78.2 million in cash, holds USD 7.5 million In Escrow and is eligible for an earn-out of up to USD 35.0 million.

Cash and cash equivalents were USD 214.9 million. Long-term Debt was USD 288.2 million, and management said USD 293 million of term Loan remained outstanding with USD 100 million available on its revolving Credit facility. Net cash provided by Operating Activities was USD 52.4 million for the nine months, against USD 67.5 million.

The company repurchased 9,009,459 shares for USD 57.4 million in the nine months, which exhausted its April 2025 program. On August 3, 2026, the board authorized a new program of up to USD 50.0 million, and no shares had been repurchased under it by September 30.

Outlook

Management narrowed its 2026 revenue growth range to 2% to 3%. It expects software growth above that range and services growth at or below the low end. The full-year adjusted EBITDA Margin outlook stays at 29% to 31%, and adjusted EPS, a non-GAAP measure, is now USD 0.31 to USD 0.34 on 155 million to 157 million diluted shares and a 25% to 30% tax rate. Management also named Grant Peterson chief product officer and said new AI capabilities should contribute to growth in 2027.